The recognition of bacterial and viral products by Toll-like receptors on cells of the innate immune system also results in NF-KappaB induction, leading to the production of proinflammatory cytokines and the activation of Antigen Presenting Cell
for T-Cell costimulation in the adaptive immune response.
Abatacept (Orencia[R], Bristol-Myers Squibb) is a selective T-cell costimulation modulator that blocks the activation of T cells by interrupting the interaction between the CD28 ligand on the T cell and the CD80/86 ligand on the antigen presenting cell
and the international Ludwig Institute for Cancer Research (LICR) have announced a multi-year clinical research collaboration focusing on a series of tumor-associated antigens (TAAs) for use in Celldex's Antigen Presenting Cell
(APC) Targeting Technology.
IMP321, a first-in-class Antigen Presenting Cell
(APC) activator based on the immune checkpoint LAG-3, represents one of the first proposed active immunotherapy drugs in which the patient's own immune system is harnessed to respond to tumour antigenic debris created by chemotherapy.
expressing tumor cells with mirvetuximab soravtansine activates monocytes, a type of antigen presenting cell
IMP321, which is a soluble form of LAG-3, is an antigen presenting cell
activator that induces T cell immunostimulation for cancer chemoimmunotherapy.
The expanded peptide-specific regulatory cells shut down the autoimmune attack by preventing aggressive autoimmune cells from being stimulated by either the peptide contained in the vaccine or by any other type 1 diabetes autoantigen presented simultaneously on the same antigen presenting cell
The method involves the loading of an antigen presenting cell
with at least one tumor associated T-cell epitope attached to an immunoglobulin backbone to form an Ig-peptide molecule ("IgNP") followed by administration the IgNP in conjunction with MCT-465, a dsRNA TLR agonist adjuvant therapeutic.
Recently, MultiCell filed the patent application entitled, "Methods for Tumor Control and Treatment by Loading an Antigen Presenting Cell
," which covers the use of MultiCell's proprietary dsRNA and Toll-like receptor (TLR) technology platform to combat malignant tumors in human patients.
In an newsletter article released today, SmallCapInsights addresses MultiCell's most recent patent announcementCo"Methods for Tumor Control and Treatment by Loading an Antigen Presenting Cell
," and provides investors with background on the Company and opinion on its progress and potential.
The patent filing, "Methods for Tumor Control and Treatment by Loading an Antigen Presenting Cell
," covers the use of MultiCell's proprietary dsRNA and Toll-like receptor (TLR) technology platform to combat malignant tumors in human patients.
APX005M is a novel, humanised investigational monoclonal antibody designed to overcome the systemic immune suppression that typically affects cancer patients through activation of CD40, a co-stimulatory receptor on the antigen presenting cells
that is essential for activating both innate and adaptive immunity.